Chapter-1: SUMMARY
DECISIVE CHANGES IN LIVES 4
WHAT DOES THE FUTURE HOLD? 5
PROJECTIONS FOR FUTURE NEEDS 5
SUMMARY TABLE PROJECTED NEEDS OF THE U.S. ELDERLY, THROUGH 2014 ($ MILLIONS) 6
SUMMARY FIGURE PROJECTED NEEDS OF THE U.S. ELDERLY, BY MARKET SEGMENT, 2008-2014 ($ MILLIONS) 6
SOURCE: BCC RESEARCH 6
Chapter-2: DEMOGRAPHICS OF THE ELDERCARE MARKET
DEFINITIONS 7
GLOBAL SOCIAL ENVIRONMENT 7
INTERGENERATIONAL LIVING ISSUES IN DEVELOPING COUNTRIES 8
INTERGENERATIONAL-LIVING ISSUES IN DEVELOPED COUNTRIES 8
GLOBAL ECONOMIC ENVIRONMENT 8
DEMOGRAPHICS IN THE UNITED STATES 9
SHIFTING DEMOGRAPHICS IN THE U.S. 9
TABLE 1 ESTIMATES FOR OVER-65 POPULATIONS BY U.S. REGION, 2007 9
RACIAL AND ETHNIC CHANGES 10
FIGURE 1 DISTRIBUTION OF OVER-65 U.S POPULATION BY RACE/ETHNICITY 2007 AND 2015 (%) 11
HEALTH OF THE ELDERLY IN THE U.S. 12
DISCREPANCIES IN MINORITY HEALTH STATUS 12
LIVING WITH LIMITATIONS 12
FIGURE 2 PREVALANCE OF CHRONIC CONDITIONS AMONG ADULTS IN THE U.S. OVER 65 YEARS OF AGE, BY RACE AND ETHNICITY (%) 13
FIGURE 3 CHRONIC CONDITIONS IN U.S. POPULATION OVER 65, 2005 (%) 14
LONG-TERM CARE SPENDING 14
FIGURE 4 U.S. NATIONAL SPENDING ON LONG-TERM CARE, BY PAYER, 2005 (%) 15
U.S. HEALTH TRENDS 15
TABLE 2 MOST COMMON CHRONIC CONDITIONS BY AGE, GENDER, AND RACE IN U.S., 2005 16
MORTALITY AND U.S. SENIORS 17
FIGURE 5 LEADING CAUSES OF U.S. DEATHS IN THOSE OVER 65, 2007 (%) 18
INDIVIDUAL BEHAVIORS AND MORTALITY 18
ECONOMIC TRENDS FOR U.S. SENIORS 19
HOUSING TRENDS FOR U.S. SENIORS 19
Housing Options 20
LIFESTYLE TRENDS FOR SENIORS IN THE U.S. 21
INTERNATIONAL DEMOGRAPHICS 21
HEALTH OF THE ELDERLY AROUND THE GLOBE 22
ECONOMIC TRENDS OUTSIDE THE U.S. 22
HOUSING TRENDS OUTSIDE THE U.S. 23
GLOBAL LIFESTYLE TRENDS OF THE ELDERLY 23
Chapter-3: OVERVIEW OF HEALTHCARE FUNDING POSSIBILITIES
U. S. AND INTERNATIONAL HEALTHCARE COSTS 24
TABLE 3 COMPARISON OF ESTIMATED GOVERNMENT HEALTHCARE SPENDING AS PERCENT OF GDP, 2007 (%/$ MILLIONS)) 24
TABLE 3 (CONTINUED) 25
FIGURE 6 PROJECTED U.S. POPULATION OVER 65, 2000-2050 (%) 25
U.S. RETIREMENT FUNDING 26
Individual Retirement Savings 26
Social Security 27
FIGURE 7 RECIPIENTS OF SOCIAL SECURITY BENEFITS, 2006 (%) 27
Social Security Beneficiaries 28
Social Security Solvency 28
Company-sponsored Pension Plans 28
GLOBAL RETIREMENT FUNDING 29
Individual Retirement Savings 29
TABLE 4 SELECTED PUBLIC AND PRIVATE PENSION EXPENDITURES, 2006 ($ MILLIONS) 29
Social Security 29
TYPES OF HEALTHCARE FUNDING IN THE U.S. 30
Private Insurance 30
Long Term Care Insurance 31
Medicare 31
Medicare Part A 32
Medicare Part B 32
Medicare Part C 33
Medicare Part D 33
Medicaid 33
Medicaid Spending and Community-based Services 34
TABLE 5 CURRENT MEDICARE/MEDICAID PAYMENTS FOR SERVICES, 2009 34
TABLE 5 (CONTINUED) 35
Medicare and Private Health Insurance Reimbursement Issues 35
Medicare Policies on Reimbursement for Powered Wheelchairs 35
Chapter-4: U.S. GOVERNMENT PROGRAMS AND LEGISLATION FOR THE ELDERLY
THE AMERICANS WITH DISABILITIES ACT 36
LITIGATION ON BEHALF OF THE ELDERLY 36
ADDITIONAL LEGISLATION 37
SAFETY AND QUALITY REGULATIONS 38
CLASS I AND II DEVICES 38
NUTRITION PROGRAMS 38
INFRASTRUCTURE CONSIDERATIONS 39
Chapter-5: INDUSTRY TRENDS BY SECTOR—HEALTHCARE
INDUSTRY TRENDS BY SECTOR—HEALTHCARE 40
TABLE 6 PROJECTED U.S. MARKET FOR ELDERCARE HEALTHCARE PRODUCTS AND SERVICES, THROUGH 2014 ($ MILLIONS) 41
ARTHRITIS 41
TABLE 7 INCIDENCE OF DIAGNOSED ARTHRITIS CASES AND CHRONIC JOINT SYMPTOMS IN THE U.S. BY AGE GROUP, 2006 (MILLION PERSONS) 42
Current Treatments 42
Medications 42
• Rheumatoid Arthritis 43
• Anticytokine Agents 43
TABLE 8 NEWER ANTICYTOKINE AGENTS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS 44
Nutritional Supplements 44
Future Arthritis Burden in the U.S. 44
FIGURE 8 FUTURE BURDEN OF ARTHRITIS FOR THOSE OVER 65 IN THE U.S., BY GENDER, 2010-2030 (MILLIONS) 45
Market for Treatments for Arthritis for the Elderly 45
TABLE 9 PROJECTED U.S. MARKET FOR PHARMACEUTICAL ARTHRITIS MEDICATIONS FOR INDIVIDUALS OVER 65, AT MANUFACTURER’S COST, THROUGH 2014 ($ MILLIONS) 46
Opportunities for Growth Related to Arthritis 46
CARDIOVASCULAR DISEASES 46
Cardiovascular Disease in the U.S. 47
Cardiovascular Disease Internationally 47
Risk Factors 47
Treatments 48
Lifestyle Changes 48
Medications 48
TABLE 10 SELECTED HEART DISEASE MEDICATIONS 49
TABLE 10 (CONTINUED) 50
TABLE 11 GLOBAL MARKET FOR CARDIOVASCULAR DISEASE MEDICATIONS, THROUGH 2014 ($ MILLIONS) 51
TABLE 12 U.S. MARKET FOR CARDIOVASCULAR DISEASE MEDICATIONS FOR THE ELDERLY, THROUGH 2014 ($ MILLIONS) 51
Surgery 51
TABLE 13 U.S. MARKET FOR CARDIOVASCULAR SURGICAL PROCEDURES FOR THE ELDERLY, THROUGH 2014 ($ MILLIONS) 52
NEUROLOGICAL DYSFUNCTIONS 53
Related Dementias and Alzheimer’s Disease 53
FIGURE 9 CAUSES OF DEMENTIA IN PEOPLE OVER 65 (%) 54
Current Treatments for Alzheimer’s 55
TABLE 14 COMMON PRESCRIPTION MEDICATIONS TO TREAT ALZHEIMER’S DISEASE 56
DEPRESSION 56
Origins of the Disease 57
Genetic Factors 57
Biological Factors 57
Sociological Factors 57
Psychological Factors 58
Risk Factors for Depression 58
Gender 58
Age 58
Marital status 58
Family History 59
Social Support 59
Family Type 59
Medical Status 59
TABLE 15 PERCENTAGE OF PATIENTS WHO REPORT BEING DEPRESSED, BY CHRONIC CONDITION (%) 60
Types of Depression 60
Prevalence of the Disorder 60
Diagnosing Depression 60
Treatment for Depression 61
TABLE 16 GLOBAL DIRECT AND INDIRECT COST OF DEPRESSION, THROUGH 2014 ($ MILLIONS) 61
Therapy 62
Antidepressant Medications 62
TABLE 17 SELECTED ANTIDEPRESSANT MEDICATIONS 62
TABLE 17 (CONTINUED) 63
• Market for Neurological Medications 63
TABLE 18 PROJECTED U.S. MARKET FOR DEMENTIA AND DEPRESSION MEDICATIONS FOR THE ELDERLY, THROUGH 2014 ($ MILLIONS) 63
CANCER 64
Types of Cancer 64
FIGURE 10 ESTIMATED NEW CASES OF CANCER IN THE U.S., 2008 (%) 65
Costs for Cancer 65
TABLE 19 PROJECTED GLOBAL COSTS FOR CANCER TREATMENTS, THROUGH 2014 ($ MILLIONS) 66
Treatment for Seniors 66
TABLE 20 PROJECTED U.S. MARKET FOR ALL TYPES OF CANCER TREATMENTS FOR INDIVIDUALS OVER 65, THROUGH 2014 ($MILLIONS) 66
DIABETES 67
Diabetes in the U.S. 67
International Prevalence 67
Origins of the Disease 68
Type 2 Diabetes 68
Complications of Diabetes 69
Barriers to Care in the U.S. 69
Diagnosing Diabetes 69
Prediabetes 70
Treatment for Type 2 Diabetes 70
Prescription Trends in Diabetes Care 71
Medications for Type 2 Diabetes 71
TABLE 21 SELECTED DIABETIC ORAL AGENTS, BY TYPE, TRADE NAME AND MANUFACTURER 72
TABLE 21 (CONTINUED) 73
TABLE 22 GLOBAL MARKET FOR DIABETIC ORAL AGENTS, THROUGH 2014 ($ MILLIONS) 73
The Elder Market for Diabetic Oral Agents 74
TABLE 23 U.S. MARKET FOR DIABETIC ORAL AGENTS FOR ADULTS OLDER THAN 65, THROUGH 2014 ($ MILLIONS) 74
Types of Insulin 74
Long-acting Insulins 75
Rapid Insulins 75
Intermediate-acting Insulin 75
Short-acting Insulin 75
TABLE 24 INSULIN MARKET IN U.S. FOR INDIVIDUALS OVER 65, THROUGH 2014 ($ MILLIONS) 76
Blood Glucose Monitoring 76
TABLE 25 SELECTED LIST OF COMPANIES MARKETING GLUCOSE MONITORING TESTS 77
TABLE 26 GLOBAL MARKET FOR BLOOD GLUCOSE MONITORING DEVICES, THROUGH 2014 ($ MILLIONS) 78
TABLE 27 U.S. BLOOD GLUCOSE MONITORING MARKET THROUGH 2014 ($ MILLIONS) 78
TABLE 28 GLOBAL BLOOD GLUCOSE MONITORING MARKET FOR INDIVIDUALS OLDER THAN 65, THROUGH 2014 ($ MILLIONS) 79
TABLE 29 U.S. BLOOD GLUCOSE MONITORING MARKET FOR INDIVIDUALS OLDER THAN 65, THROUGH 2014 ($ MILLIONS) 79
Rationale for the Use of Blood Glucose Monitors 79
Nutrition and Exercise 80
COMMUNICATION DISORDERS 81
Speech Impairments 81
Writing Difficulties 81
Sensory Disabilities 81
Vision Loss 81
TABLE 30 PREVALENCE OF AGE-RELATED EYE DISEASES, 2004 (%) 82
TABLE 30 (CONTINUED) 83
Eyeglass Market 83
FIGURE 11 U.S. MARKET FOR EYEGLASSES AND CONTACTS IN 2007 (%) 84
Market for Vision Loss Products 84
TABLE 31 PROJECTED U.S. EYEWEAR SALES, THROUGH 2014 ($ MILLIONS) 85
Market for Eyewear Products for Seniors 85
TABLE 32 PROJECTED U.S. EYEWEAR SALES FOR INDIVIDUALS OVER 65, THROUGH 2014 ($ MILLIONS) 85
Cataracts 86
TABLE 33 PROJECTED COST OF CATARACT SURGERY FOR INDIVIDUALS OVER 65, THROUGH 2014 ($ MILLIONS) 86
Hearing Loss 86
TABLE 34 SELECTED HEARING AID MANUFACTURERS 87
TABLE 35 REPORTED INCIDENCE OF HEARING PROBLEMS AMONG U.S. ADULTS BY SEX/AGE GROUP, 2006 (%) 88
Projected Senior Market for Hearing Aids 88
TABLE 36 PROJECTED U.S. MARKET FOR HEARING AIDS FOR INDIVIDUALS OVER 65, AT RETAIL PRICING, THROUGH 2014 ($ MILLIONS)* 88
Cochlear Implants 89
Communication Aids 89
Speech Recognition 89
Vocal Output Technology 89
Developments in Communication Technology 90
Mobile Location Technology 90
Sensor Technology 90
Visual and Reading Aids 91
TABLE 37 2007 VISION AND READING AIDS SALES 91
Newer adaptive technologies 91
MEMS-based Hearing Aids 92
Telephony Accessories 92
Vision and Reading Aids 92
Video Magnifiers 92
ORTHOPEDIC IMPAIRMENTS 93
TABLE 38 PROJECTED TRENDS IN NUMBER OF U.S. TOTAL HIP AND KNEE REPLACEMENTS, THROUGH 2014 (THOUSANDS OF PROCEDURES) 94
TABLE 39 U.S. ORTHOPEDIC IMPLANT MARKET BY NUMBER AND TYPE OF PROCEDURE, THROUGH 2014 94
Orthopedic Implant Market for Elders 94
TABLE 40 PROJECTED U.S. AND REST OF THE WORLD ORTHOPEDIC IMPLANT MARKET GROWTH, THROUGH 2014 ($ MILLIONS) 95
TABLE 41 PROJECTED U.S. COSTS OF ORTHOPEDIC SURGERY FOR INDIVIDUALS OVER 65, THROUGH 2014 ($ MILLIONS) 95
Orthobiologic Market 96
TABLE 42 GLOBAL ORTHOBIOLOGICS MARKET, BY PRODUCT, THROUGH 2014 ($ MILLIONS) 96
Orthobiologics and Implications for Falls and the Elderly 96
RESPIRATORY CONDITIONS 97
Allergies and Asthma 97
ASTHMA 97
Origins of the Disease 98
Treatments 98
TABLE 43 SELECTED LIST OF COMMON ALLERGY/ASTHMA MEDICATIONS 99
TABLE 44 SELECTED LISTING OF INHALED CORTICOSTEROIDS 100
Costs for Asthma Medications 100
TABLE 45 GLOBAL COSTS FOR ASTHMA MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2014 ($ MILLIONS) 100
TABLE 46 U.S. COSTS FOR ASTHMA MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2014 ($ MILLIONS) 101
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) 101
Costs of COPD in the U.S, 101
Home Use of Oxygen and Respiratory Supplies 102
Costs of Respiratory Care 102
TABLE 47 PROJECTED COSTS OF HOME OXYGEN AND RESPIRATORY SUPPLIES FOR INDIVIDUALS OVER 65, THROUGH 2014 ($ MILLIONS) 102
OTHER CHRONIC CONDITIONS 103
Dental Health 103
Osteoporosis 103
Age-related Loss of Strength/Balance/Coordination 104
UROLOGICAL PROBLEMS 104
Incontinence Medications 105
TABLE 48 PROJECTED MARKET FOR INCONTINENCE MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2014 ($ MILLIONS) 105
Benign Prostatic Hyperplasia (BPH) 105
TABLE 49 SELECTED MEDICATIONS FOR BPH 106
TABLE 50 PROJECTED U.S. MARKET FOR BPH MEDICATIONS FOR INDIVIDUALS OVER 65, THROUGH 2014 ($ MILLIONS) 106
OBESITY 106
TABLE 51 GLOBAL MARKET FOR PRESCRIPTION WEIGHT LOSS PRODUCTS THROUGH 2014 ($ MILLIONS) 107
Chapter-6: INDUSTRY TRENDS BY SECTOR—HOUSING/PERSONAL CARE
TABLE 52 PROJECTED HOUSING MARKETS FOR SENIORS OVER 65, THROUGH 2014 ($ MILLIONS) 108
OPTIONS FOR HOUSING 109
REMODELING TO REMAIN AT HOME 109
TABLE 53 PROJECTED SPENDING ON HOME RENOVATION PROJECTS BY INDIVIDUALS OVER 65, THROUGH 2014 ($ MILLIONS) 109
COSTS OF AT-HOME SENIOR SERVICES CARE 110
TABLE 54 AVERAGE ANNUAL COST OF HOME CARE SERVICES, 2008 ($) 111
TABLE 55 PROJECTED MARKET FOR HOME CARE SERVICES, THROUGH 2014 ($ MILLIONS) 111
ADULT DAY CENTERS 111
ALTERNATIVE COMMUNITIES 112
Independent Living Communities 112
Recreationally Based Retirement Communities 113
Assisted Living 113
Costs for Assisted Living 114
TABLE 56 PROJECTED GROWTH OF ASSISTED-LIVING COSTS IN THE U.S. FOR INDIVIDUALS OVER 65, THROUGH 2014 ($ MILLIONS) 115
Nursing Care 115
Paying for Skilled Nursing Services 115
TABLE 57 PROJECTED MARKET FOR SKILLED NURSING FACILITIES FOR INDIVIDUALS OVER 65, THROUGH 2014 ($ MILLIONS) 116
Alzheimer’s Care 116
Costs of Alzheimer’s Care 116
UNPAID CAREGIVERS 117
PAID CAREGIVERS 117
Toll on Caregivers 118
LONG-TERM CARE 118
FIGURE 12 PROJECTED LIFETIME LONG-TERM CARE NEEDS FOR INDIVIDUALS OVER 65 (%) 119
END-OF-LIFE CONSIDERATIONS 119
Legal Matters 119
Hospice and Alzheimer’s 120
Hospice Costs and Alzheimer’s Disease 120
MARKET OPPORTUNITIES IN ELDERCARE HOME SERVICES AND HOUSING OPTIONS 120
Market Opportunities in …(Continued) 121
Chapter-7: INDUSTRY TRENDS BY SECTOR—ASSISTIVE TECHNOLOGY
TABLE 58 PROJECTED U.S. ASSISTIVE TECHNOLOGY SALES FOR THE ELDERCARE MARKET, THROUGH 2014 ($ MILLIONS) 122
HOME SAFETY PRODUCTS/SERVICES 123
ACTIVITY LOCATION/PERSONAL MONITORING AIDS 123
Activity/Emergency Location Monitors 123
Remote Medical Monitors 123
TABLE 59 SELECTED MEDICAL/PERSONAL MONITORING AID MANUFACTURERS 124
MARKET GROWTH 124
TABLE 60 PROJECTED U.S. SALES OF MEDICAL/PERSONAL MONITORING AIDS FOR INDIVIDUALS OVER 65, THROUGH 2014 ($ MILLIONS) 124
MARKET DRIVERS 125
Market Fragmentation 125
DAILY LIVING AIDS 125
TABLE 61 SELECTED DAILY LIVING AIDS MANUFACTURERS 126
FIGURE 13 DAILY LIVING MARKET, BY SEGMENT AND TOTAL PERCENT OF SALES, 2007 (%) 126
FIGURE 14 PERCENT OF TOTAL SALES FOR OTHER DAILY LIVING AIDS, 2007 (%) 127
The Market for Daily Living Aids 127
TABLE 62 PROJECTED U.S. SALES OF DAILY LIVING AIDS FOR INDIVIDUALS OVER 65, THROUGH 2014 ($ MILLIONS) 128
Market Share by Company 128
TABLE 63 DAILY LIVING AIDS MANUFACTURERS, SALES AND PERCENT OF MARKET, 2007 ($ MILLIONS/PERCENT) 128
Incontinence Product Market 129
TABLE 64 PROJECTED U.S. SALES OF INCONTINENCE AND OSTOMY PRODUCTS, THROUGH 2014 ($ MILLIONS) 129
BATHING AIDS 129
Commode and Shower Chairs 129
TABLE 65 PROJECTED U.S. SALES OF COMMODE AND SHOWER CHAIRS TO INDIVIDUALS OVER 65, THROUGH 2014 ($ MILLIONS) 130
MOBILITY AIDS 130
TABLE 66 REPORTED INCIDENCE OF IMPAIRED MOBLITY AND DEXTERITY IN THE U.S. BY SEX/AGE GROUP, 2006 (%) 131
TABLE 67 PROJECTED U.S. MARKET FOR MOBILITY PRODUCTS FOR INDIVIDUALS OVER 65, THROUGH 2014 ($ MILLIONS) 131
AMBULATORY AIDS 132
TABLE 68 SELECTED AMBULATORY AID MANUFACTURERS 132
Ambulatory Aids Usage and Demographics 132
TABLE 69 PROJECTED U.S. SALES OF AMBULATORY AIDS FOR INDIVIDUALS OVER 65, THROUGH 2014 ($ MILLIONS) 133
WHEELCHAIR/SCOOTER USE 133
Medicare Reimbursement for Powered Wheelchairs 134
MARKET SHARE LEADERS 134
TABLE 70 SELECTED LIST OF WHEELCHAIR AND SCOOTER MANUFACTURERS 134
TABLE 70 (CONTINUED) 135
TABLE 71 WHEELCHAIR TYPES AND PERCENT OF MARKET, 2007 (%) 135
MARKET DRIVERS 135
TABLE 72 PROJECTED U.S, MARKET FOR WHEELCHAIR/SCOOTER MOBILITY PRODUCTS FOR THE ELDERLY, THROUGH 2014 ($ MILLIONS) 136
Special Purpose Wheelchairs 136
MOTOR VEHICLE CONVERSIONS 136
NAVIGATION AIDS 137
Ultrasound Guidance Systems 137
GPS Systems 138
TABLE 73 SELECTED NAVIGATION AIDS MANUFACTURERS 138
ACCESS AIDS 138
MARKET FOR ACCESS AIDS 139
TABLE 74 PROJECTED U.S. SALES OF ACCESS AID PRODUCTS BY SEGMENT, THROUGH 2014 ($ MILLIONS) 139
TABLE 75 PROJECTED U.S. SALES OF ACCESS AID PRODUCTS FOR INDIVIDUALS OVER 65, BY SEGMENT, THROUGH 2014 ($ MILLIONS) 139
HOME ELEVATORS 140
WHEELCHAIR LIFTS 140
STAIR CLIMBERS 140
ACCESSIBLE BATHS AND SHOWERS 140
SPECIAL COMMODES 140
BATH AND POOL LIFTS 141
TRANSFER LIFTS 141
DOOR OPENERS 141
TABLE 76 SELECTED ACCESS AID MANUFACTURERS 141
OTHER AIDS 142
TABLE 77 SELECTED MANUFACTURERS OF BED, SEATING, AND ERGONOMIC AIDS FOR THE ELDERLY 142
TABLE 78 PROJECTED MARKET FOR BEDS, SEATING SYSTEMS, AND ERGONOMIC AIDS FOR INDIVIDUALS OVER 65, THROUGH 2014 ($ MILLIONS) 143
Beds, Seating 143
Bariatric Beds 144
Seating and Positioning Systems 144
Ergonomic Aids 144
TABLE 79 EXAMPLES HAVE ERGONOMIC AIDS FOR THE ELDERLY 145
Computer Access Aids 145
Input Devices 145
Output Devices 145
Computer Software 146
TABLE 80 SELECTED COMPUTER AID MANUFACTURERS 146
ENVIRONMENTAL AIDS 146
TABLE 81 SELECTED ENVIRONMENTAL AID MANUFACTURERS 147
ASSISTIVE TECHNOLOGIES UNDER DEVELOPMENT 147
ELECTRONICS 148
Mobile Location Technology 148
Sensor Technology 148
Artificial Intelligence 148
ENERGY SOURCES 149
MINIATURIZATION 149
Chapter-8: COMPANY DIRECTORY
ABBOTT LABORATORIES 150
BUSINESS OVERVIEW 150
FINANCIALS 150
PRODUCTS 150
ASTRAZENECA PLC 151
BUSINESS OVERVIEW 151
FINANCIALS 151
PRODUCTS 151
BAY ADVANCED TECHNOLOGIES, LTD. 151
BUSINESS OVERVIEW 152
FINANCIALS 152
PRODUCTS 152
BAYER AG (MILES-BAYER) 152
BUSINESS OVERVIEW 152
FINANCIALS 152
PRODUCTS 153
BRISTOL-MYERS SQUIBB 153
BUSINESS OVERVIEW 153
FINANCIALS 153
PRODUCTS 153
BROOKDALE SENIOR LIVING 153
BUSINESS OVERVIEW 154
FINANCIALS 154
PRODUCTS 154
CENTOCOR 154
BUSINESS OVERVIEW 154
FINANCIALS 154
PRODUCTS 155
COVIDIEN 155
BUSINESS OVERVIEW 155
FINANCIALS 155
PRODUCTS 155
ELI LILLY 155
BUSINESS OVERVIEW 156
FINANCIALS 156
PRODUCTS 156
FOREST PHARMACEUTICALS 156
BUSINESS OVERVIEW 156
FINANCIALS 157
PRODUCTS 157
GENENTECH, INC. 157
BUSINESS OVERVIEW 157
FINANCIALS 157
PRODUCTS 157
GLAXOSMITHKLINE PLC 158
BUSINESS OVERVIEW 158
FINANCIALS 158
PRODUCTS 158
GRAHAM-FIELD HEALTH PRODUCTS 158
BUSINESS OVERVIEW 159
FINANCIALS 159
PRODUCTS 159
HONEYWELL HOMMED, LLC 159
BUSINESS OVERVIEW 159
FINANCIALS 159
PRODUCTS 159
HUMANWARE 160
FINANCIALS 160
PRODUCTS 160
INVACARE CORP. 160
BUSINESS OVERVIEW 160
FINANCIALS 160
PRODUCTS 161
JOHNSON & JOHNSON 161
BUSINESS OVERVIEW 161
FINANCIAL INFORMATION 161
PRODUCTS 161
KIMBERLY CLARK 162
BUSINESS OVERVIEW 162
FINANCIALS 162
PRODUCTS 162
KINDRED HEALTHCARE 162
BUSINESS OVERVIEW 162
FINANCIALS 162
PRODUCTS 163
LIFE ALERT EMERGENCY RESPONSE 163
BUSINESS OVERVIEW 163
FINANCIALS 163
PRODUCTS 163
LIFE CARE CENTERS OF AMERICA 163
BUSINESS OVERVIEW 164
FINANCIALS 164
PRODUCTS 164
LIFE GUARDIAN LLC 164
BUSINESS OVERVIEW 164
FINANCIALS 164
PRODUCTS 165
LIVHOME, INC. 165
BUSINESS OVERVIEW 165
FINANCIALS 165
PRODUCTS 165
HCR MANOR CARE 165
BUSINESS OVERVIEW 166
FINANCIALS 166
PRODUCTS 166
MAXHEALTH CORPORATON 166
BUSINESS OVERVIEW 166
FINANCIALS 166
PRODUCTS 166
MEDLINE INDUSTRIES, INC. 167
BUSINESS OVERVIEW 167
FINANCIALS 167
PRODUCTS 167
MERCK & CO INC 167
BUSINESS OVERVIEW 167
FINANCIAL INFORMATION 168
PRODUCTS 168
NOVARTIS AG 168
BUSINESS OVERVIEW 168
FINANCIALS 168
PRODUCTS 169
NOVO NORDISK 169
BUSINESS OVERVIEW 169
FINANCIALS 169
PRODUCTS 169
OPTELEC 170
BUSINESS OVERVIEW 170
FINANCIALS 170
PRODUCTS 170
ORTHO-MCNEIL 170
BUSINESS OVERVIEW 170
FINANCIALS 171
PRODUCTS 171
PFIZER 171
BUSINESS OVERVIEW 171
FINANCIALS 171
PRODUCTS 172
PHILIPS LIFELINE SYSTEMS, INC. 172
BUSINESS OVERVIEW 172
FINANCIALS 172
PRODUCTS 172
PHONAK AG 172
BUSINESS OVERVIEW 173
FINANCIALS 173
PRODUCTS 173
PRIDE MOBILITY PRODUCTS CORP. 173
BUSINESS OVERVIEW 173
FINANCIALS 173
PRODUCTS 173
ROCHE PHARMACEUTICALS 174
BUSINESS OVERVIEW 174
FINANCIALS 174
PRODUCTS 174
SANOFI-AVENTIS 174
BUSINESS OVERVIEW 175
FINANCIALS 175
PRODUCTS 175
SAVARIA CONCORD LIFTS, INC. 175
BUSINESS OVERIEW 175
FINANCIALS 175
PRODUCTS 176
SCA (SVENSKA CELLULOSA AKTIEBOLAGET) 176
BUSINESS OVERVIEW 176
FINANCIALS 176
PRODUCTS 176
SCHERING-PLOUGH 176
BUSINESS OVERVIEW 177
FINANCIALS 177
PRODUCTS 177
SIEMENS HEARING INSTRUMENTS, INC. 177
BUSINESS OVERVIEW 177
FINANCIALS 177
PRODUCTS 178
STARKEY LABORATORIES 178
BUSINESS OVERVIEW 178
FINANCIALS 178
PRODUCTS 178
SUNRISE MEDICAL, INC. 178
BUSINESS OVERVIEW 179
FINANCIALS 179
PRODUCTS 179
SUNRISE SENIOR LIVING 179
BUSINESS OVERVIEW 179
FINANCIALS 179
PRODUCTS 180
TAKEDA PHARMACUETICALS 180
BUSINESS OVERVIEW 180
FINANCIALS 180
PRODUCTS 180
THORNDIKE PRESS 180
BUSINESS OVERVIEW 181
FINANCIALS 181
PRODUCTS 181
THYSSENKRUPP ACCESS 181
BUSINESS OVERVIEW 181
FINANCIALS 181
PRODUCTS 181
TYCO INTERNATIONAL 182
BUSINESS OVERVIEW 182
FINANCIALS 182
PRODUCTS 182
WIDEX 182
BUSINESS OVERVIEW 182
FINANCIALS 183
PRODUCTS 183
WYETH 183
BUSINESS OVERVIEW 183
FINANCIALS 183
PRODUCTS 184
Chapter-9: APPENDIX
APPENDIX 185
DEFINITIONS 185
ACTIVITIES OF DAILY LIVING (ADLS) 185
ALZHEIMER’S DISEASE 185
ARTHRITIS 185
ASSISTIVE TECHNOLOGY 185
ASSISTED LIVING 186
BABY BOOMER 186
CAREGIVERS 186
CARDIOVASCULAR DISEASE (CVD) 186
CONGESTIVE OBSTRUCTIVE PULMONARY DISEASE (COPD) 186
DEMENTIA 186
DIABETES 187
DURABLE MEDICAL EQUIPMENT 187
ELDER/SENIOR 187
GERONTOLOGY 187
HOSPICE CARE 187
INSTRUMENTAL ACTIVITIES OF DAILY LIVING (IADL) 187
LONG-TERM CARE 188
PROSTHETICS AND ORTHOTICS 188
